136 related articles for article (PubMed ID: 36154839)
1. Validation of a highly sensitive Sanger sequencing in detecting EGFR mutations from circulating tumor DNA in patients with lung cancers.
Jiang H; Chen X; Huang F; Xu X; Dong B; Luo J; Yang H; Zhang C; Pan B; Wang B; Guo W
Clin Chim Acta; 2022 Nov; 536():98-103. PubMed ID: 36154839
[TBL] [Abstract][Full Text] [Related]
2. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
Li Y; Zhang FS; Guo L; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
[No Abstract] [Full Text] [Related]
3. [Clinical Value of Droplet Digital PCR and Super-ARMS Detection of Epidermal Growth Factor Receptor Gene Mutation in Plasma Circulating Tumor DNA of Patients with Advanced Lung Adenocarcinoma].
Cao Z; Wang J; Qin N; Li K; Lv J; Wang J; Yang X; Li X; Zhang H; Zhang Q; Long H; Shu C; Ma L; Zhang S
Zhongguo Fei Ai Za Zhi; 2020 Feb; 23(2):84-90. PubMed ID: 32093452
[TBL] [Abstract][Full Text] [Related]
4. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
[TBL] [Abstract][Full Text] [Related]
5. Detection of
Bai H; Xia J; Zhao X; Gong Z; Zhang D; Xiong L
J Clin Pathol; 2019 May; 72(5):379-385. PubMed ID: 30787028
[TBL] [Abstract][Full Text] [Related]
6. The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance.
O'Kane GM; Liu G; Stockley TL; Shabir M; Zhang T; Law JH; Le LW; Sacher A; Shepherd FA; Bradbury PA; Leighl NB
Lung Cancer; 2019 May; 131():86-89. PubMed ID: 31027703
[TBL] [Abstract][Full Text] [Related]
7. Construction of a reference material panel for detecting
Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
[TBL] [Abstract][Full Text] [Related]
8. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
[TBL] [Abstract][Full Text] [Related]
9. Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling.
Tran HT; Lam VK; Elamin YY; Hong L; Colen R; Elshafeey NA; Hassan ISA; Altan M; Blumenschein GR; Rinsurongkawong W; Rivera MJ; Vasquez ME; Carter BW; Byers LE; Tsao AS; Gibbons DL; Fossella F; Glisson BS; Zhang J; Heymach JV
JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34377884
[TBL] [Abstract][Full Text] [Related]
10. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
[TBL] [Abstract][Full Text] [Related]
11. Correlation of epidermal growth factor receptor mutation status in plasma and tissue samples of patients with non-small cell lung cancer.
Roh MS; Yoon NB; Lee S; Kang BH; Um SJ; Lee DH; Son C
J Cancer Res Ther; 2020; 16(4):843-849. PubMed ID: 32930128
[TBL] [Abstract][Full Text] [Related]
12. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
13. Detection of EGFR Mutations in Circulating Tumor DNA (ctDNA) Retrieved from Plasma - Interlaboratory Quality Assessment in the Czech Republic.
Linda Č; Markéta K; Ivana T; Eva P; Milada M; Hana V; Ondřej H; Karolína B; Jiří D; Monika B; Pavel D
Klin Onkol; 2018; 31(5):353-360. PubMed ID: 30541321
[TBL] [Abstract][Full Text] [Related]
14. Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients.
Dono M; De Luca G; Lastraioli S; Anselmi G; Dal Bello MG; Coco S; Vanni I; Grossi F; Vigani A; Genova C; Ferrarini M; Ravetti JL; Zupo S
Mol Med; 2019 Apr; 25(1):15. PubMed ID: 31029076
[TBL] [Abstract][Full Text] [Related]
15. Analytical and clinical validation of an amplicon-based next generation sequencing assay for ultrasensitive detection of circulating tumor DNA.
Poh J; Ngeow KC; Pek M; Tan KH; Lim JS; Chen H; Ong CK; Lim JQ; Lim ST; Lim CM; Goh BC; Choudhury Y
PLoS One; 2022; 17(4):e0267389. PubMed ID: 35486650
[TBL] [Abstract][Full Text] [Related]
16. Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.
Gupta R; Othman T; Chen C; Sandhu J; Ouyang C; Fakih M
Oncologist; 2020 Mar; 25(3):235-243. PubMed ID: 32162812
[TBL] [Abstract][Full Text] [Related]
17. Analytical validation of the Target Selector ctDNA platform featuring single copy detection sensitivity for clinically actionable EGFR, BRAF, and KRAS mutations.
Poole JC; Wu SF; Lu TT; Vibat CRT; Pham A; Samuelsz E; Patel M; Chen J; Daher T; Singh VM; Arnold LJ
PLoS One; 2019; 14(10):e0223112. PubMed ID: 31581267
[TBL] [Abstract][Full Text] [Related]
18. A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance.
Wang W; Song Z; Zhang Y
Cancer Med; 2017 Jan; 6(1):154-162. PubMed ID: 28000387
[TBL] [Abstract][Full Text] [Related]
19. Detection of plasma EGFR mutations for personalized treatment of lung cancer patients without pathologic diagnosis.
Deng Q; Fang Q; Sun H; Singh AP; Alexander M; Li S; Cheng H; Zhou S
Cancer Med; 2020 Mar; 9(6):2085-2095. PubMed ID: 31991049
[TBL] [Abstract][Full Text] [Related]
20. The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment.
Sueoka-Aragane N; Nakashima C; Yoshida H; Matsumoto N; Iwanaga K; Ebi N; Nishiyama A; Yatera K; Kuyama S; Fukuda M; Ushijima S; Umeguchi H; Harada D; Kashiwabara K; Suetsugu T; Fujimoto N; Tanaka F; Uramoto H; Yoshii C; Nakatomi K; Koh G; Seki N; Aoe K; Nosaki K; Inoue K; Takamori A; Kawaguchi A
Cancer Med; 2021 Jun; 10(12):3873-3885. PubMed ID: 33982444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
